0001209191-20-002630.txt : 20200108 0001209191-20-002630.hdr.sgml : 20200108 20200108201817 ACCESSION NUMBER: 0001209191-20-002630 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200107 FILED AS OF DATE: 20200108 DATE AS OF CHANGE: 20200108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nichols Garrett CENTRAL INDEX KEY: 0001618364 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 20516861 MAIL ADDRESS: STREET 1: C/O CHIMERIX, INC. STREET 2: 2505 MERIDIAN PARKWAY, SUITE 340 CITY: DURHAM STATE: NC ZIP: 27713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-07 0 0001117480 CHIMERIX INC CMRX 0001618364 Nichols Garrett C/O CHIMERIX, INC. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 0 1 0 0 Chief Medical Officer Common Stock 2020-01-07 4 S 0 30680 2.1527 D 271421 D The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Includes 2,045 shares of the Issuer's common stock acquired by the reporting person on September 10, 2019 pursuant to an employee stock purchase program. /s/ Michael Alrutz, Attorney-in-Fact 2020-01-08